The latest edition of Pharmalytics – Report No. 8 (Q2 2026) is now available to Pharma.Aero members, offering an executive analysis of the developments that shaped pharmaceutical and life sciences logistics during the second quarter of 2026.
As geopolitical uncertainty increasingly influences global trade, the pharmaceutical supply chain is entering a new phase where resilience depends less on reacting to disruption and more on anticipating structural change. This edition explores how trade policy, manufacturing strategies, investment decisions and regional market dynamics are reshaping the global healthcare logistics landscape.
Q2 2026 – Key Insights & Expert Perspectives
-
Editorial Column | Six Years In, Still Riding Out the Storm
by Roel Gevaers, Antwerp Management School – UAntwerpen - From trade flows to exposure maps
How U.S. pharmaceutical and API imports reveal the next phase of logistics resilience - Pharma market developments
The Next Decade of the Active Pharmaceutical Ingredient Market – Strategic Shifts in Manufacturing, Supply Chains and Global Healthcare (2026–2035) - Pharma & Life Sciences Logistics Markets Q2 2026
Local Mergers, Global Investments and Geopolitical Shifts – The most strategically significant developments of the quarter
Accessing the Report
The Pharmalytics Q2 2026 report is available exclusively to Pharma.Aero members via the secure members’ area. This public article serves as an overview only; detailed data, analysis, and insights remain confidential.